Issues related to development of new anti-seizure treatments

This report represents a summary of the discussions led by the anti-seizure treatment working group of the ILAE/AES Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacological characteristics of current models of refractory seizures, both...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsia (Copenhagen) 2013-08, Vol.54 (4), p.24-34
Main Authors: Wilcox, Karen S., Dixon-Salazar, Tracy, Sills, Graeme J., Ben-Menachem, Elinor, White, H. Steve, Porter, Roger J., Dichter, Marc A., Moshé, Solomon L., Noebels, Jeffery L., Privitera, Michael D., Rogawski, Michael A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This report represents a summary of the discussions led by the anti-seizure treatment working group of the ILAE/AES Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacological characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the NINDS-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacological development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.
ISSN:0013-9580
1528-1167
DOI:10.1111/epi.12296